Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
A Prospective, Real-World Study of Alternating Hepatic Arterial Infusion Chemotherapy and Systemic Chemotherapy With or Without Adebrelimab and Apatinib in Patients With Unresectable Biliary Tract Cancer
研究概览
详细说明
Biliary tract cancer (BTC), which includes intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer, is an aggressive malignancy associated with a generally poor prognosis. For patients with unresectable, locally advanced, or metastatic disease, first-line systemic chemotherapy using gemcitabine and cisplatin remains the standard of care, although treatment outcomes are ofter suboptimal. HAIC has gained increasing attention in clinical practice, paticularly in China, for its ability to enhance local drug delivery and improve tumor control in cases of liver-dominant disease. Alternating HAIC with systemic chemotherapy may provide additive benefits by simultaneously targeting both intrahepatic and extrahepatic lesions.
Recent advances in immunotherapy and anti-angiogenic therapy have shown promise results in BTC. Adebrelimab, a PD-L1 inhibitor, and apatinib, a VEGFR2 inhibitor, have demonstrated antitumor activity in various solid tumors. Combining these agents with chemotherapy and HAIC may yield synergistic effects, potentially improving response rates and extending survival.
This prospective real-world study is designed to evaluate the effectiveness and safety of an alternating regimen of HAIC and systemic chemotherapy (gemcitabine plus cisplatin), with or without adebrelimab and apatinib, in patients with previously untreated, unresectable, locally advanced or metastatic BTC. Participants will be assigned to one of two cohorts based on patient preference and clinician judgment: Cohort A will receive HAIC and systemic chemotherapy combined with adebrelimab and apatinib, while Cohort B will receive HAIC and systemic chemotherapy alone. Dosing and administration will follow the standard treatment protocols.
The study will capture real-world data on objective tumor response, progression-free survival, overall survival, and safety profiles. Exploratory analyses may include patterns of disease progression, treatment adherence, and the influence of clinical and biological factors on outcomes. The results are anticipated to offer valuable evidence to guide clinical decision-making and help optimize first-line treatment strategies for patients with advanced BTC in routine practice.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名：Jun Tie, Dr
- 电话号码：+8618629507963
- 邮箱：tiejun7776@163.com
学习地点
-
-
Shaanxi
-
Xi'an、Shaanxi、中国、710032
- 招聘中
- Air Force Military Medical University
-
接触：
- Jun Tie, M.D.,Ph.D. Jun Tie, M.D.,Ph.D.
- 电话号码：+862984771537
- 邮箱：tiejun7776@163.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Age ≥ 18 years at the time of enrollment.
- Histologically or cytologically confirmed diagnosis unresectable, locally advanced, or metastatic BTC, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer.
- No prior systemic therapy for BTC, including chemotherapy, immunotherapy, or small-molecule targeted therapy.
- Patients with disease recurrence ≥6 months after curative resection and completion of adjuvant therapy (chemotherapy or radiotherapy) are eligible.
- Adequate liver function: defined as Child-Pugh Class A (score 5-6) or well-compensated Class B (score ≤7).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- At least one measurable lesion as defined by RECIST 1.1.
- Assessed by the investigator as being able to tolerate and comply with the study treatment regimen.
- Provision of written informed consent, voluntarily agreeing to participate after full explanation of the study protocol.
Exclusion Criteria:
- Hepatic tumor burden occupying ≥50% of total liver volume.
- History of liver transplantation.
- Major surgery or invasive procedure (excluding intravenous catheter placement or percutaneous drainage) within 4 weeks prior to enrollment.
- History or evidence of clinically significant bleeding, including: bleeding >30 mL within 3 months prior to enrollment (including hematemesis, melena, or hematochezia), hemoptysis (>5 mL of fresh blood) within 4 weeks prior to enrollment, or thromboembolic events (including stroke or transient ischemic attack) within the past 12 months.
- Known active infection with human immunodeficiency virus (HIV).
- Pregnant (a positive pregnancy test prior to study drug administration) or breastfeeding women.
- Any condition, in the investigator's judgment, that could compromise patient satety, affect the assessment of study outcomes, or lead to premature discontinuation. this includes, but is not limited to: active alcohol or substance abuse, severe uncontrolled comorbidities, significant laboratory abnormalities, or social/family circumstances that could interfere with protocol compliance.
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：非随机化
- 介入模型：并行分配
- 屏蔽：双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Alternating HAIC and Systemic Chemotherapy Plus Adebrelimab and Apatinib
Participants in this arm will receive alternating cycles of HAIC and systemic chemotherapy with gemcitabine plus cisplatin, combined with adebrelimab (1200 mg every 3 weeks) and apatinib (250 mg orally once daily).
The dosing and administration of HAIC and systemic chemotherapy follow each center's standard treatment protocols.
|
HAIC is administered using a gemcitabine plus cisplatin regimen, with dosing and administration according to each participating center's standard treatment protocols.
Gemcitabine and cisplatin administered intravenously according to institutional standard first-line regimens for biliary tract cancer.
Dosing and schedule follow each center's standard treatment protocols.
Adebrelimab administered intravenously at a dose of 1200 mg every 3 weeks until disease progression or unacceptable toxicity.
Apatinib administered orally at a dose of 250 mg once daily until disease progression or unacceptable toxicity.
|
|
有源比较器：Alternating HAIC and Systemic Chemotherapy Alone
Participants in this arm will receive alternating cycles of HAIC and systemic chemotherapy with gemcitabine plus cisplatin.
The dosing and administration of HAIC and systemic chemotherapy follow each center's standard treatment protocols.
|
HAIC is administered using a gemcitabine plus cisplatin regimen, with dosing and administration according to each participating center's standard treatment protocols.
Gemcitabine and cisplatin administered intravenously according to institutional standard first-line regimens for biliary tract cancer.
Dosing and schedule follow each center's standard treatment protocols.
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival (OS)
大体时间：The maximum time from receiving treatment to dying for any reason is 3 years.
|
Overall survival (OS) was defined as the time from initiation of study treatment (first dose) to death from any cause.
|
The maximum time from receiving treatment to dying for any reason is 3 years.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-free Survival (PFS)
大体时间：Progression-free survival (PFS) analysis based on investigator assessment per RECIST 1.1, and will be assessed up to 2 years.
|
Progression-free survival (PFS), assessed by investigators per RECIST version 1.1, was defined as the time from initiation of study treatment (first dose) to the first documentation of objective disease progression or death from any cause, which ever occurred first.
|
Progression-free survival (PFS) analysis based on investigator assessment per RECIST 1.1, and will be assessed up to 2 years.
|
|
Objective Response Rate (ORR)
大体时间：Every 6 weeks for the first 24 weeks, then every 8 weeks until disease progression or study completion, up to 1 years.
|
Disease assessments based on investigator assessments were determined by using RECIST version 1.1 guidelines.
The ORR was defined as the percentage of patients with confirmed complete response (CR) or confirmed partial response (PR).
The CR was defined as disappearance of all target and non-target lesions and no new lesions.
The PR was defined as >= 30% decrease in the sum of diameters of target lesions (compared to baseline) and no new non-target lesion.
|
Every 6 weeks for the first 24 weeks, then every 8 weeks until disease progression or study completion, up to 1 years.
|
|
Disease Control Rate (DCR)
大体时间：Every 6 weeks for the first 24 weeks, then every 8 weeks until disease progression or study completion, up to 1 years.
|
Disease control rate based on investigator assessments according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR), partial response (PR) or stable disease (SD).
|
Every 6 weeks for the first 24 weeks, then every 8 weeks until disease progression or study completion, up to 1 years.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.